SCHEMBL30612152

SCHEMBL30612152

O=C1c2ccccc2C(=O)N1c1nn(C2COC2)c2c(Br)cc(Cl)nc12

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HTT P42858 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ ESR1 P03372 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ PKM P14618 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ APEX1 P27695 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ RECQL P46063 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ PTK2B Q14289 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26107180 1.00 ALDH1A1 (0.32) ALDH1A1GAAHTTMEN1ESR1
SCHEMBL30611994 0.90 ALDH1A1 (0.33) ALDH1A1GAAHTTMEN1CYP3A4
SCHEMBL26106122 0.90 ALDH1A1 (0.33) ALDH1A1GAAHTTMEN1CYP3A4
SCHEMBL26108650 0.85 ALDH1A1 (0.31) ALDH1A1GAA
SCHEMBL30611905 0.85 ALDH1A1 (0.31) ALDH1A1GAA
SCHEMBL30612052 0.85 ALDH1A1 (0.31) ALDH1A1GAA
SCHEMBL26107765 0.85 ALDH1A1 (0.31) ALDH1A1GAA
SCHEMBL30612041 0.81 PDCD1LG2 (0.35) MEN1MAPTKMT2A
SCHEMBL30612067 0.81 — —
SCHEMBL26106666 0.81 PDCD1LG2 (0.35) MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 — — US disclosed
CN-119585252-A Bicyclic heteroaryl containing compounds as IKZF2 degrading agents 翁科皮亚治疗公司和SK生命科学实验室 2025-03-07 — — CN disclosed
EP-4499629-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2025-02-05 — — EP disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 ALDH1A1 3438/4885GAA 1225/4885HTT 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback